S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:ENOB

Enochian Biosciences Stock Forecast, Price & News

$3.28
+0.11 (+3.47 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.12
Now: $3.28
$3.30
50-Day Range
$2.87
MA: $3.07
$3.46
52-Week Range
$1.95
Now: $3.28
$13.43
Volume133,519 shs
Average Volume139,029 shs
Market Capitalization$152.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1621st out of 1,925 stocks

Pharmaceutical Preparations Industry

690th out of 773 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENOB
CUSIPN/A
CIKN/A
Phone510-203-4857
Employees10

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.58 per share

Profitability

Net Income$-11,420,000.00

Miscellaneous

Market Cap$152.97 million
Next Earnings DateN/A
OptionableNot Optionable
$3.28
+0.11 (+3.47 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENOB News and Ratings via Email

Sign-up to receive the latest news and ratings for ENOB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Enochian Biosciences (NASDAQ:ENOB) Frequently Asked Questions

How has Enochian Biosciences' stock price been impacted by Coronavirus (COVID-19)?

Enochian Biosciences' stock was trading at $2.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENOB stock has increased by 45.8% and is now trading at $3.28.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Enochian Biosciences?

Wall Street analysts have given Enochian Biosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enochian Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Enochian Biosciences' CEO?

1,448 employees have rated Enochian Biosciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Enochian Biosciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Enochian Biosciences' key competitors?

What other stocks do shareholders of Enochian Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioScience (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and LiveXLive Media (LIVX).

Who are Enochian Biosciences' key executives?

Enochian Biosciences' management team includes the following people:
  • Dr. Mark R. Dybul M.D., Exec. Vice Chairman & Principal Exec. Officer (Age 58, Pay $430k)
  • Ms. Luisa Puche, Chief Financial Officer (Age 58, Pay $280k)
  • Dr. Serhat Gümrükcü, Co-Founder & Inventor
  • Dr. Wenshi Wang, Sr. VP of Operations

What is Enochian Biosciences' stock symbol?

Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB."

How do I buy shares of Enochian Biosciences?

Shares of ENOB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enochian Biosciences' stock price today?

One share of ENOB stock can currently be purchased for approximately $3.28.

How big of a company is Enochian Biosciences?

Enochian Biosciences has a market capitalization of $152.97 million. Enochian Biosciences employs 10 workers across the globe.

What is Enochian Biosciences' official website?

The official website for Enochian Biosciences is www.enochianbio.com.

How can I contact Enochian Biosciences?

Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The company can be reached via phone at 510-203-4857 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.